Sienna Biopharmaceuticals Inc (SNNAQ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
60
30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE, CA 91362
(818) 629-2256

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

Data derived from most recent annual or quarterly report
Market Cap 412.624 Thousand Shares Outstanding22.924 Million Avg 30-day Volume 86.118 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.13
Price to Revenue0.0 Debt to Equity0.0 EBITDA-51.617 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value0
Current Ratio15.272 EPS Growth-1.393 Quick Ratio8.771
1 Yr BETA -0.5964 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth9.2165 Altman Z-Score0.0 Free Cash Flow to Firm -35.359 Million
View SEC Filings from SNNAQ instead.

View recent insider trading info

Sienna Biopharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SNNAQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SNNAQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2019-10-04 by AZOY ALEXANDER
  • 4: filed on 2019-08-08 by AZOY ALEXANDER
  • 4: filed on 2019-08-08 by LIZZUL PAUL F.
  • 4: filed on 2019-07-03 by ANDREWS TIMOTHY K.
  • 4: filed on 2019-07-03 by LIZZUL PAUL F.
  • 4: filed on 2019-07-03 by AZOY ALEXANDER
  • 4: filed on 2019-07-03 by BEDDINGFIELD III FREDERICK
  • 4: filed on 2019-06-03 by BUROW KRISTINA
  • 4: filed on 2019-06-03 by MORE ROBERT J
  • 4: filed on 2019-06-03 by LEONARD KEITH R

    • Events (8k)

  • 8-K: filed on 2019-12-11:
    Item 8.01: Other Events
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2019-11-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-09-23:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-09-17:
    Item 1.03: Bankruptcy or Receivership
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2019-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-02-22:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-02-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-01-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-01-02:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    AZOY ALEXANDER CHIEF FINANCIAL OFFICER

    • Officer
    		 103,552 2019-10-02 0

    BEDDINGFIELD III FREDERICK PRESIDENT & CEO

    • Officer
    • Director
    		 1,542,181 2019-08-06 0

    LIZZUL PAUL F. CHIEF MEDICAL OFFICER

    • Officer
    		 327,595 2019-08-06 0

    ANDREWS TIMOTHY K. GENERAL COUNSEL & SECRETARY

    • Officer
    		 193,058 2019-08-06 0

    STROEHMANN DIANE SEE REMARKS

    • Officer
    		 168,545 2019-07-02 0

    FENTON DENNIS M

    • Director
    		 26,250 2019-05-30 0

    MORE ROBERT J

    • Director
    		 280,942 2019-05-30 0

    LEONARD KEITH R

    • Director
    		 173,484 2019-05-30 0

    BUROW KRISTINA

    • Director
    • 10% Owner
    		 5,823,868 2019-05-30 0

    HINDMAN JAMES M.

    • Director
    		 25,000 2019-05-30 0

    HARRIS TODD

    • Director
    		 595,991 2019-05-30 0

    ARCH VENTURE PARTNERS VIII, LLC

    ARCH VENTURE FUND VIII, L.P.

    ARCH VENTURE FUND VIII OVERAGE, L.P.

    ARCH VENTURE PARTNERS VIII, L.P.

    BYBEE CLINTON

    CRANDELL KEITH

    NELSEN ROBERT

    • 10% Owner
    		 2,898,293 2019-02-22 0

    ARCH VENTURE PARTNERS X, LLC

    ARCH VENTURE FUND X OVERAGE, L.P.

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

    CRANDELL KEITH

    NELSEN ROBERT

    GILLIS STEVEN

    • 10% Owner
    		 2,898,293 2019-02-22 0

    SMITHER JOHN W CHIEF FINANCIAL OFFICER

    • Officer
    		 141,040 2019-01-01 0

    MAST ERLE T

    • Director
    		 16,700 2018-06-01 0

    NELSEN ROBERT

    • Director
    • 10% Owner
    		 3,643,068 2018-06-01 0

    ARCH VENTURE PARTNERS VIII, LLC

    ARCH VENTURE PARTNERS VIII, L.P.

    ARCH VENTURE FUND VIII, L.P.

    ARCH VENTURE FUND VIII OVERAGE, L.P.

    BYBEE CLINTON

    CRANDELL KEITH

    • 10% Owner
    		 3,633,068 2017-08-01 0

    PETERSON RICHARD D CHIEF FINANCIAL OFFICER

    • Officer
    		 7,000 2017-08-01 0

    ARCH VENTURE PARTNERS VIII, LLC

    • 10% Owner
    		 0 2017-07-26 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 22:15:04 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 21:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 21:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 20:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 20:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 19:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 19:15:04 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 18:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 18:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 17:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 17:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 16:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 16:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 15:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 15:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 14:45:02 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 14:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 13:45:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 13:15:03 UTC -1.2814 1.3514 250000
    SIENNA BIOPHARMACEUTICALS IN SNNAQ 2021-10-15 12:45:03 UTC -1.2814 1.3514 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments